CAS 1562993-37-6

Ponatinib-d8

CAS: 1562993-37-6

Fórmula: C₂₉H₁₉D₈F₃N₆O

Cor e Forma: Pale Yellow Solid

Peso molecular: 540.62

Ref: 4Z-P-123002

Ponatinib-d8

CAS: 1562993-37-6

Ponatinib D8 is a deuterium-enriched, oral multi-kinase inhibitor (Abl, PDGFRα, VEGFR2, FGFR1, Src; IC50s: 0.37-5.4 nM).

Fórmula: C₂₉H₂₇F₃N₆O

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 540.61

Ref: TM-T12521

Ponatinib-d8

Produto Controlado

CAS: 1562993-37-6

Applications Ponatinib-d8 is an isotope labelled compound of Ponatinib (P688250). Ponatinib is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3). Ponatinib is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. It is a COVID19-related research product.
References Skora, L., et al.: ACS Med. Chem. Lett., PagesAhead of Print (2017); Uchibori, K., et al.: Nat. Commun., 8, 14768 (2017); Perrotti, D., et al.: Curr. Drug Targets, 18, 377 (2017); Santarpia, M., et al.: Trans. Lung Cancer Res., 5, 51 (2016); Halbach, S., et al.: Cell Commun. Signal., 14, 6 (2016)

Fórmula: C₂₉H₁₉D₈F₃N₆O

Cor e Forma: Neat

Peso molecular: 540.61

Ref: TR-P688252